Department of Medical Oncology (Breast Cancer), Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.
Department of Clinical Medicine, Wenzhou Medical University, Wenzhou, People's Republic of China.
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231173504. doi: 10.1177/15330338231173504.
Recent studies have demonstrated that the combination of Cyclin-Dependent Kinase 4/6 Inhibitor (CDK4/6i) and endocrine therapy (ET) is more effective than ET alone and significantly improves progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) breast cancer (BC). Palbociclib is the first CDK4/6i approved for use, and its clinical advantages have been shown. However, 30% of patients will continue to develop secondary drug resistance. Therefore, exploring the parameters that can predict the efficacy of Palbociclib and developing a clinical prediction model is essential for evaluating the prognosis of patients.
最近的研究表明，细胞周期蛋白依赖性激酶 4/6 抑制剂（CDK4/6i）与内分泌治疗（ET）联合应用比单独 ET 更有效，可显著改善激素受体阳性（HR+）/人表皮生长因子受体 2 阴性（HER2-）乳腺癌（BC）患者的无进展生存期（PFS）和总生存期（OS）。帕博西利是首个获批用于临床的 CDK4/6i，其临床优势已得到证实。然而，仍有 30%的患者会出现继发耐药。因此，探索能够预测帕博西利疗效的参数并建立临床预测模型对于评估患者的预后至关重要。
